

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

_____)
IN RE SALIX PHARMACEUTICALS, LTD.) Case No. 14 Civ. 8925 (KMW)
_____) CLASS ACTION
_____)

**SUPPLEMENTAL DECLARATION OF STEPHANIE A. THURIN
REGARDING (A) MAILING OF NOTICE AND CLAIM FORM;
AND (B) REPORT ON REQUESTS FOR EXCLUSION RECEIVED**

I, STEPHANIE A. THURIN, declare as follows:

1. I am a Project Manager at Epiq Class Action & Claims Solutions, Inc. (“Epiq”). Pursuant to the Court’s April 5, 2017 Order Preliminarily Approving Proposed Settlement and Providing for Notice (ECF No. 220) (the “Preliminary Approval Order”), Epiq was authorized to act as the Claims Administrator in connection with the Settlement of the above-captioned action (the “Action”).¹ I submit this Declaration as a supplement to my earlier declaration, the Declaration of Stephanie A. Thurin Regarding (A) Mailing of the Notice and Claim Form; (B) Publication of the Summary Notice; and (C) Report on Requests for Exclusion Received to Date, dated June 16, 2017 (ECF No. 225-1) (the “Initial Mailing Declaration”). I have personal knowledge of the facts set forth herein and, if called as a witness, could and would testify competently thereto.

MAILING OF THE NOTICE PACKET

2. Since the execution of my Initial Mailing Declaration, Epiq has continued to disseminate copies of the Notice and Claim Form (the “Notice Packet”) in response to additional requests from potential members of Settlement Class, brokers, and nominees. Through July 14,

¹ Unless otherwise defined herein, all capitalized terms have the meanings set forth in Stipulation and Agreement of Settlement dated March 24, 2017 (ECF No. 216-1).

2017, Epiq has mailed a total of 73,898 Notice Packets to potential Settlement Class Members and nominees.


TELEPHONE HELPLINE AND WEBSITE

3. Epiq continues to maintain the toll-free telephone number (1-844-308-6864) and interactive voice response system to accommodate any inquiries from potential members of the Settlement Class. Epiq also continues to maintain the dedicated website for the Action (www.SalixSecuritiesLitigation.com) in order to assist potential members of the Settlement Class. On June 20, 2017, Epiq posted to the website copies of the papers filed in support of the motion for final approval of the Settlement and Plan of Allocation and in support of Lead Counsel's motion for an award of attorneys' fees and expenses. Epiq will continue maintaining and, as appropriate, updating the website and toll-free telephone number until the conclusion of the administration.

REPORT ON REQUESTS FOR EXCLUSION RECEIVED

4. The Notice informed potential members of the Settlement Class that requests for exclusion from the Settlement Class were to be mailed or otherwise delivered, addressed to *In re Salix Pharmaceuticals, Ltd.*, EXCLUSIONS, c/o Epiq Systems, P.O. Box 3656, Portland, OR 97208-3656, such that they were received by no later than July 5, 2017. Epiq has been monitoring all mail delivered to that post office box. As of the date of this Declaration, Epiq has received four (4) requests for exclusion. Of these requests, three (3) were received before the July 5, 2017 deadline. The fourth request (from Margaret C. Maddox) was postmarked on July 3, 2017 and received by Epiq on July 6, 2017. Exhibit 1 attached lists the names of the persons and entities who have requested exclusion from the Settlement Class and their city and state.

I declare under penalty of perjury that the foregoing is true and correct. Executed on July 17, 2017.



Stephanie A. Thurin

#1095346

Exhibit 1

1. Hoplite Partners, L.P.
Hoplite Offshore Master Fund, Ltd.
New York, NY
2. Incline Global Master LP
Incline Global ELS LP
New York, NY
3. Margaret C. Maddox
Redondo Beach, CA
4. Edgar A. Pelfrey
Fort Wayne, IN